版本:
中国

BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono

Nov 25 Opexa Therapeutics Inc

* Opexa Therapeutics - On Nov 23, co received notice from Ares Trading S.A. Unit of Merck Serono

* Opexa Therapeutics - Notice says Merck Serono would not be exercising its option to acquire exclusive worldwide license to co's Tcelna Program for MS

* Says as a result of receiving notice from Merck Serono, agreement automatically expired upon receipt Source text: [bit.ly/2gtrjR7] Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐